VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age 65 years and older                             │ Age 65 years and older                             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypertension - untreated (Systolic Blood Pressure  │ Hypertension - untreated (Systolic Blood Pressure  │     100 │
│ (SBP) ≥ 140 mm Hg or Diastolic Blood Pressure      │ (SBP) ≥ 140 mm Hg or Diastolic Blood Pressure      │         │
│ (DBP) ≥ 90 mm Hg) or treated                       │ (DBP) ≥ 90 mm Hg) or treated                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Physical limitations evidenced by either           │ Physical limitations evidenced by either           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Score ≤ 10 on the Short Physical Performance       │ Score ≤ 10 on the Short Physical Performance       │     100 │
│ Battery OR Walking speed \< 1.2 m/sec during 400 m │ Battery OR Walking speed < 1.2 m/sec during 400 m  │         │
│ usual-paced test                                   │ usual-paced test                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Sedentary lifestyle, defined as \<150 min/wk of    │ Sedentary lifestyle, defined as <150 min/wk of     │     100 │
│ moderate physical activity as assessed by CHAMPS   │ moderate physical activity as assessed by CHAMPS   │         │
│ questionnaire                                      │ questionnaire                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Willingness to participate in all study procedures │ Willingness to participate in all study procedures │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Failure to provide informed consent                │ Failure to provide informed consent                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Inability to complete 400 m walk within 15 minutes │ Inability to complete 400 m walk within 15 minutes │     100 │
│ without sitting or interpersonal assistance, as an │ without sitting or interpersonal assistance, as an │         │
│ indicator of disablement and likely inability to   │ indicator of disablement and likely inability to   │         │
│ fully engage in the exercise intervention          │ fully engage in the exercise intervention          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Primary indication for ACE inhibitor use, i.e.     │ Primary indication for ACE inhibitor use, i.e.     │     100 │
│ Congestive Heart Failure, CAD, diabetes            │ Congestive Heart Failure, CAD, diabetes            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to ACE inhibitors           │ Known hypersensitivity to ACE inhibitors           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Resistant hypertension, defined as BP \> 140/90,   │ Resistant hypertension, defined as BP > 140/90,    │     100 │
│ despite the use of three or more anti-hypertensive │ despite the use of three or more anti-hypertensive │         │
│ drugs                                              │ drugs                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Primary renal disease                              │ Primary renal disease                              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Abnormal liver enzymes (Aspartate transaminase     │ Abnormal liver enzymes (Aspartate transaminase     │     100 │
│ (AST), Alanine transaminase (ALT), or alkaline     │ (AST), Alanine transaminase (ALT), or alkaline     │         │
│ phosphatase \> 2.5 times the upper limit of        │ phosphatase > 2.5 times the upper limit of normal) │         │
│ normal)                                            │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe cardiac disease, including New York Heart   │ Severe cardiac disease, including New York Heart   │     100 │
│ Association Class III or IV congestive heart       │ Association Class III or IV congestive heart       │         │
│ failure, clinically significant aortic stenosis,   │ failure, clinically significant aortic stenosis,   │         │
│ history of cardiac arrest, use of a cardiac        │ history of cardiac arrest, use of a cardiac        │         │
│ defibrillator, or uncontrolled angina              │ defibrillator, or uncontrolled angina              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Acute myocardial infarction identified by ECG      │ Acute myocardial infarction identified by ECG      │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Lives in a nursing home (persons living in         │ Lives in a nursing home (persons living in         │     100 │
│ assisted or independent housing will not be        │ assisted or independent housing will not be        │         │
│ excluded)                                          │ excluded)                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Significant cognitive impairment, defined as a     │ Significant cognitive impairment, defined as a     │     100 │
│ known diagnosis of dementia or a Mini-Mental State │ known diagnosis of dementia or a Mini-Mental State │         │
│ Examination exam score \< 24                       │ Examination exam score < 24                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unable to communicate because of severe hearing    │ Unable to communicate because of severe hearing    │     100 │
│ loss or speech disorder                            │ loss or speech disorder                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Severe visual impairment, which would preclude     │ Severe visual impairment, which would preclude     │     100 │
│ completion of the assessments and/or intervention  │ completion of the assessments and/or intervention  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other significant co-morbid disease that would     │ Other significant co-morbid disease that would     │     100 │
│ prevent participation in exercise                  │ prevent participation in exercise                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Planning to move out of the area during the study  │ Planning to move out of the area during the study  │     100 │
│ time frame                                         │ time frame                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Simultaneous participation in another intervention │ Simultaneous participation in another intervention │     100 │
│ trial                                              │ trial                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum creatinine \>2.5 mg/dL in men, or \>2.0      │ Serum creatinine >2.5 mg/dL in men, or >2.0 mg/dL  │      98 │
│ mg/dL in women                                     │ in women                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Urinary protein \> 1 on dipstick                   │ Urinary protein > 1 on dipstick                    │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Office or average home SBP \> 180 mm Hg or DBP \>  │ Office or average home SBP > 180 mm Hg or DBP >    │      99 │
│ 110 mm Hg (Average home BP in any seven day period │ 110 mm Hg (Average home BP in any seven day period │         │
│ during trial)                                      │ during trial)                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum potassium \>5.0 molar equivalent/L           │ Serum potassium >5.0 molar equivalent/L            │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                       │   Score │
╞═══════════════════════════════════╪═════════════════════════════════════╪═════════╡
│ Must have minimum age of 65 Years │ Failure to provide informed consent │      38 │
╘═══════════════════════════════════╧═════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 97.48148148148148
OverAll Ratio: 98.24074074074073
